Cargando…

Neoadjuvant immunotherapy for resectable esophagal squamous cell carcinoma: An ace up the sleeve

Detalles Bibliográficos
Autores principales:	Zhou, Qing, Yuan, Jingnan, Wu, Kui, Yin, Jun, Tan, Lijie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514370/ https://www.ncbi.nlm.nih.gov/pubmed/37735826 http://dx.doi.org/10.1002/ctm2.1426

Ejemplares similares

Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
por: Yin, Jun, et al.
Publicado: (2023)

Publisher Correction: Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
por: Yin, Jun, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC)
por: Li, Chunguang, et al.
Publicado: (2022)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Bronchial sleeve resection for early-stage squamous cell carcinoma
por: Goto, Taichiro, et al.
Publicado: (2012)

ACE up the sleeve – are vascular patients medically optimized?
por: Coveney, AP, et al.
Publicado: (2011)

The prognostic significance of the circumferential resection margin in esophageal squamous cell carcinoma patients without neoadjuvant treatment
por: Yang, Zhaoyang, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis
por: Yu, Guocan, et al.
Publicado: (2021)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

The predictive value of microRNAs for pathological response after neoadjuvant treatment in esophageal squamous cell carcinoma: a systematic review
por: Lin, Dong, et al.
Publicado: (2021)

Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?
por: Xu, Yaping, et al.
Publicado: (2012)

Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma
por: Yan, Mao-Hui, et al.
Publicado: (2020)

Nectin-4 inhibitors: An ace up our sleeve against advanced urothelial carcinoma
por: Kumaraswamy, Santosh
Publicado: (2021)

Immunotherapy for Esophageal Squamous Cell Carcinoma
por: Kojima, Takashi, et al.
Publicado: (2017)

B-Hex, an ace up the sleeve for small pupil phacoemulsification
por: Sarosh, Rimsha, et al.
Publicado: (2022)

Artificial Intelligence in Hypertension Management: An Ace up Your Sleeve
por: Visco, Valeria, et al.
Publicado: (2023)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
por: Zhu, Jie, et al.
Publicado: (2022)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma
por: FUJIWARA, YOSHINORI, et al.
Publicado: (2013)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

Effect of circumferential resection margin status on survival and recurrence in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy
por: Gu, Yi-Min, et al.
Publicado: (2022)

A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy
por: Yu, Yongkui, et al.
Publicado: (2022)

Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer
por: Xu, Ke, et al.
Publicado: (2021)

Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs
por: Zhang, Zhihui, et al.
Publicado: (2021)

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
por: Zhao, Junfeng, et al.
Publicado: (2023)

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy
por: Jiang, Dongxian, et al.
Publicado: (2023)

ACE2 and Diabetes: ACE of ACEs?
por: Batlle, Daniel, et al.
Publicado: (2010)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014)

Commentary: Anatomic resection after neoadjuvant TKI therapy—To be forewarned
por: Chang, Andrew C.
Publicado: (2021)

GASC1-Adapted Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Prospective Clinical Biomarker Trial
por: Jia, Ruinuo, et al.
Publicado: (2020)

A Novel Predictor of Pathologic Complete Response for Neoadjuvant Immunochemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Yang, Yalan, et al.
Publicado: (2023)

Deguelin, a Novel Anti-Tumorigenic Agent in Human Esophageal Squamous Cell Carcinoma
por: Baba, Yuh, et al.
Publicado: (2017)

Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery
por: Wang, Xingxing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m64luts6vbjqmvruuo0dumre8t